HomeCompareINRLF vs PLD

INRLF vs PLD: Dividend Comparison 2026

INRLF yields 63.90% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.12M in total portfolio value· pulled ahead in Year 9
10 years
INRLF
INRLF
● Live price
63.90%
Share price
$3.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$787.3K
Annual income
$193,029.75
Full INRLF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — INRLF vs PLD

📍 PLD pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINRLFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INRLF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INRLF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INRLF
Annual income on $10K today (after 15% tax)
$5,431.31/yr
After 10yr DRIP, annual income (after tax)
$164,075.29/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,874,041.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INRLF + PLD for your $10,000?

INRLF: 50%PLD: 50%
100% PLD50/50100% INRLF
Portfolio after 10yr
$3.35M
Annual income
$2,471,877.47/yr
Blended yield
73.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

INRLF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.2
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INRLF buys
0
PLD buys
0
No recent congressional trades found for INRLF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINRLFPLD
Forward yield63.90%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$787.3K$5.91M
Annual income after 10y$193,029.75$4,750,725.19
Total dividends collected$660.4K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: INRLF vs PLD ($10,000, DRIP)

YearINRLF PortfolioINRLF Income/yrPLD PortfolioPLD Income/yrGap
1$17,090$6,389.78$11,241$540.96+$5.8KINRLF
2$28,492$10,205.59$13,019$991.13+$15.5KINRLF
3$46,387$15,901.41$15,801$1,870.97+$30.6KINRLF
4$73,830$24,195.53$20,609$3,701.21+$53.2KINRLF
5$114,988$35,990.20$29,919$7,867.97+$85.1KINRLF
6$175,424$52,386.69$50,631$18,617.74+$124.8KINRLF
7$262,396$74,691.78$105,528$51,352.20+$156.9KINRLF
8$385,177$104,413.37$287,364$174,449.42+$97.8KINRLF
9← crossover$555,383$143,243.74$1,081,760$774,280.77$526.4KPLD
10$787,290$193,029.75$5,908,209$4,750,725.19$5.12MPLD

INRLF vs PLD: Complete Analysis 2026

INRLFStock

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Full INRLF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this INRLF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INRLF vs SCHDINRLF vs JEPIINRLF vs OINRLF vs KOINRLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.